Jennifer Woyach, MD, on CLL/SLL: Pirtobrutinib vs Ibrutinib in Treatment-Naive and Relapsed/Refractory Disease
ASH 2025
Jennifer Woyach, MD, of The Ohio State University Comprehensive Cancer Center, discusses results from the first head-to-head comparison of pirtobrutinib vs ibrutinib in treatment-naive patients and patients with covalent Bruton tyrosine kinase inhibitor–naive relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (Abstract 683).
The ASCO Post Staff
Shahzad Raza, MD, of Cleveland Clinic, presents updated phase II results of the RedirecTT-1 trial, focusing on the efficacy and safety of talquetamab combined with teclistamab in patients with relapsed/refractory multiple myeloma and extramedullary disease (Abstract 698). The study also received simultaneous publication in The New England Journal of Medicine.
The ASCO Post Staff
Amer Zeidan, MBBS, of Yale School of Medicine, shares results from the phase I/II BEXMAB study, which examined the safety, tolerability and preliminary efficacy of bexmarilimab—a novel macrophage checkpoint inhibitor targeting Clever-1—in combination with the standard of care, azacitidine, in patients with higher-risk myelodysplastic syndromes (MDS), including those with TP53-mutated disease. (Abstract 236).
The ASCO Post Staff
Jack Khouri, MD, of Cleveland Clinic, describes the findings of a phase II trial which investigated the safety and efficacy of burixafor (GPC-100), a potent and selective small -molecule antagonist of CXCR4, and propranolol with granulocyte colony-stimulating factor (G-CSF) for the mobilization of hematopoietic progenitor cells (HPC) in patients with multiple myeloma. Researchers aimed to boost the bone marrow HPC niche and optimize mobilization in patients with multiple myeloma eligible for autologous hematopoietic cell transplant (Abstract 1050).
The ASCO Post Staff
Amer Zeidan, MBBS, of Yale School of Medicine, discusses findings from an analysis of the IMerge trial, which explored the possible association between imetelstat-related cytopenias and hemoglobin increase—a measure linked to red blood cell transfusion independence achievement—in patients with lower-risk myelodysplastic syndromes (MDS) (Abstract 490).
The ASCO Post Staff
Othman Al-Sawaf, MD, PhD, of the University Hospital of Cologne, presents results from the phase III CLL17 trial, which compared continuous ibrutinib monotherapy to fixed-duration venetoclax plus obinutuzumab to fixed-duration venetoclax plus ibrutinib for previously untreated patients with chronic lymphocytic leukemia (CLL) (Abstract 1).